通过与二硫化相关的基因和免疫景观分析,对莫亚莫亚病分子亚型的表征
Yanru Wang1, Yutao Su1, Junze Zhang1,2
1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, P.R. China.
Experimental and therapeutic medicine
|February 27, 2025
概括
不硫化,一种新的细胞死亡途径,与莫亚莫亚病 (MMD) 病原发生有关. 四个枢纽基因 (WDR27,OSBPL11,MSOM1,NEIL2) 被确定为MMD亚型和相关免疫功能障碍的潜在生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 遗传学 是一个遗传学.
背景情况:
- 莫亚莫亚病 (MMD) 涉及内动脉的渐进性狭窄,其潜在机制尚不清楚.
- 溶硫脱症是一种新发现的细胞死亡模式,与actin细胞骨压力有关.
- 以前的研究表明,MMD中的内皮细胞增殖可能涉及焦点粘附蛋白.
研究的目的:
- 为了调查二硫化在莫亚莫亚病病原发生中的作用.
- 根据与二硫化相关的基因表达,识别MMD的分子亚型.
- 发现MMD诊断和分类的潜在生物标志物.
主要方法:
- 从基因表达总量数据库下载并分析了四个微阵列数据集.
- 进行了差异基因表达分析和功能丰富分析.
- 使用斯皮尔曼和皮尔森分析确定了枢纽基因,分析了免疫细胞透和相关的基因表达.
- 使用ELISA验证的枢纽基因表达.
主要成果:
- 根据二硫化的基因表达,将MMD分为三个分子亚型.
- 在MMD患者中鉴定了348个上调和801个下调的基因.
- 选择了四个枢纽基因 (WDR27,OSBPL11,MSOM1,NEIL2) 作为潜在的MMD生物标志物.
- 在枢纽基因,免疫细胞透和内皮细胞迁移/增殖之间发现了显著的相关性.
结论:
- 据推测,二硫化症在莫亚莫亚病的发病过程中起作用.
- 确定了新的MMD分子亚型和潜在的诊断生物标志物.
- 与二硫化症亚型相关的免疫失调可能会导致MMD中的内皮细胞异常.
- 这项研究首次探讨了MMD和二硫症之间的联系,为疾病机制提供了新的见解.
相关概念视频
01:23Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...